1216-44-0

Basic information

• Product Name: FLURENOL-METHYL ESTER
• Synonyms: FLURENOL-METHYL;FLURENOL-METHYL ESTER;METHYL 9-HYDROXYFLUORENE-9-CARBOXYLATE;METHYL 9-HYDROXYFLUOROENE-9-CARBOXYLATE;9-Hydroxy-9-Fluorene Carboxylic Acid Methyl Ester;FLURENOL-METHYL ESTER PESTANAL, 250 MG;flurecol methyl ester (bsi before 1990);flurenol-methyl(bsi,iso)
• CAS NO: 1216-44-0
• Molecular Formula: C₁₅H₁₂O₃
• Molecular Weight: 240.25
• Mol File: 1216-44-0.mol
• Article Data: 13

Chemical Properties

• Melting Point: 158-163°C
• Boiling Point: 336.2 °C at 760 mmHg
• Flash Point: 100 °C
• Appearance: /
• Density: 1.324 g/cm³
• Vapor Pressure: 4.46E-05mmHg at 25°C
• Refractive Index: 1.651
• Storage Temp.: 0-6°C
• PKA: 11.17±0.20(Predicted)
• BRN: 2943173
• CAS DataBase Reference: FLURENOL-METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: FLURENOL-METHYL ESTER(1216-44-0)
• EPA Substance Registry System: FLURENOL-METHYL ESTER(1216-44-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1216-44-0(Hazardous Substances Data)

Usage

General Description

Fluorenol-methyl ester is a chemical compound that is used in the field of organic chemistry. It is derived from fluorenol, a substance with potential pharmacological properties, and is modified through the addition of a methyl ester group. This modification can alter the compound's physical and chemical properties, potentially making it more or less reactive or soluble in different solvents. Fluorenol-methyl ester may have applications in the development of pharmaceuticals, as well as in research and development for the synthesis of new organic compounds. It is important to handle fluorenol-methyl ester with care and follow proper safety protocols, as its chemical properties can present potential hazards if mishandled.

InChI:InChI=1/C15H12O3/c1-18-14(16)15(17)12-8-4-2-6-10(12)11-7-3-5-9-13(11)15/h2-9,17H,1H3

Upstream product

• 467-69-6 9-hydroxy-9-fluorene carboxylic acid 
• 84-11-7 9,10-phenanthrenequinone 
• 486-25-9 9-fluorenone 
• 139022-32-5 diethyl 9H-fluorene-9,9-dicarboxylate 
• 138723-90-7 2,5-dihydro-2,2-dimethoxy-5,5-dimethyl-1,3,4-oxadiazole 
• 3002-30-0 methyl 9H-fluorene-9-carboxylate 
• 67-56-1 methanol 

Downstream Products

• 131807-68-6 3'-(Phenylamino)-2'-thioxo-spiro(9H-fluorene-9,5'-oxazolidin)-4'-one 
• 575433-63-5 tropenol 9-hydroxy-fluorene-9-carboxylate 
• 14718-07-1 10,10-diphenyl-10H-phenanthren-9-one 
• 109399-94-2 9-hydroxy-fluorene-9-carboxylic acid-(4-bromo-anilide) 
• 872267-20-4 9-(hydroxy-di-m-tolyl-methyl)-fluorenol-⁽⁹⁾ 
• 858799-33-4 9-[hydroxy-bis-(4-methoxy-phenyl)-methyl]-fluorenol-⁽⁹⁾ 
• 109746-94-3 9-hydroxy-fluorene-9-carboxylic acid anilide 
• 876498-21-4 9-(α-hydroxy-4,4'-dimethyl-benzhydryl)-fluoren-9-ol 

Relevant articles and documents

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: Identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2. 2.2]octane bromide (aclidinium bromide)

The objective of this work was to discover a novel, long-acting muscarinicM3 antagonist for the inhaled treatment of chronic obstructive pulmonary disease (COPD), with a potentially improved risk-benefit profile compared with current antimuscarinic agents. A series of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters were synthesized and evaluated. On the basis of its overall profile, (3R)-3-{[hydroxy(di-2-thienyl) acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidiniumbromide) emerged as a candidate for once-daily maintenance treatment of COPD. This compound is a potent muscarinic antagonist, with long duration of action in vivo, and was found to have a rapid hydrolysis in human plasma, minimizing the potential to induce class-related systemic side effects. Aclidinium bromide is currently in phase III development for maintenance treatment of patients with COPD.

MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC

The present invention relates to novel pharmaceutical compositions comprising one or more, preferably one anticholinergic 1 and a betamimetic of formula 2 processes for preparing them and their use in the treatment of respiratory complaints.

Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments

Flourenecarboxylic acid esters of general formula 1 wherein X? and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.